HEMO vs. 4BB, BVXP, TILS, VSN, SCLP, MPH, HVO, ORPH, REDX, and ETX
Should you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include 4basebio (4BB), Bioventix (BVXP), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), hVIVO (HVO), Open Orphan (ORPH), Redx Pharma (REDX), and e-therapeutics (ETX). These companies are all part of the "biotechnology" industry.
Hemogenyx Pharmaceuticals vs. Its Competitors
Hemogenyx Pharmaceuticals (LON:HEMO) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.
Hemogenyx Pharmaceuticals has a beta of 3.14, indicating that its share price is 214% more volatile than the S&P 500. Comparatively, 4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
Hemogenyx Pharmaceuticals' return on equity of -80.66% beat 4basebio's return on equity.
Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Hemogenyx Pharmaceuticals had 2 more articles in the media than 4basebio. MarketBeat recorded 2 mentions for Hemogenyx Pharmaceuticals and 0 mentions for 4basebio. Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.
1.3% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of 4basebio shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Comparatively, 12.0% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
4basebio has a consensus price target of GBX 1,600, indicating a potential upside of 90.48%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Hemogenyx Pharmaceuticals.
Summary
Hemogenyx Pharmaceuticals beats 4basebio on 7 of the 13 factors compared between the two stocks.
Get Hemogenyx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hemogenyx Pharmaceuticals Competitors List
Related Companies and Tools
This page (LON:HEMO) was last updated on 9/13/2025 by MarketBeat.com Staff
Free HEMO Stock Alerts